Form 4: Adverum Biotechnologies CEO Acquires Shares and Stock Options
SEC Form 4 Filing
CEO Laurent Fischer reports acquisition of shares and stock options in Adverum Biotechnologies.
Summary
- Laurent Fischer, CEO, President, and Director of Adverum Biotechnologies, reported changes in beneficial ownership.
- On February 25, 2025, Fischer acquired 25,000 shares of Common Stock upon settlement of a restricted stock unit (RSU) grant.
- These RSUs will vest in equal installments on each anniversary of March 1, 2025, over three years, contingent upon continued service.
- Fischer also acquired a stock option to purchase 150,000 shares of Common Stock at an exercise price of $4.20.
- The stock options vest over four years from March 1, 2025.
- Following these transactions, Fischer directly owns 96,614 shares of Common Stock and holds options for 150,000 shares.
- The report also mentions a 1-for-10 stock split that occurred on March 21, 2024, which proportionately reduced the Reporting Person's shares.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock transactions. The CEO's increased stake could be seen as mildly positive.
Positives
- The CEO's acquisition of shares and stock options could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology industry.
Comparison to Industry Standards
- Executive compensation packages in biotech often include stock options and RSUs to align management's interests with shareholders.
- The vesting schedules described are fairly standard, with vesting occurring over several years contingent on continued employment.
- Comparing the size of the option grant and RSU award to those of CEOs at similarly sized biotech companies would provide further context.
Stakeholder Impact
- The CEO's increased ownership stake could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| May 20, 2023 | 600 shares purchased on May 20, 2023, pursuant to the Issuer's 2014 Employee Stock Plan Purchase Plan, as amended and restated. |
| November 20, 2023 | 600 shares purchased on November 20, 2023, pursuant to the Issuer's 2014 Employee Stock Plan Purchase Plan, as amended and restated. |
| March 21, 2024 | Common Stock of Issuer split 1-for-10. |
| May 20, 2024 | 600 shares purchased on May 20, 2024, pursuant to the Issuer's 2014 Employee Stock Plan Purchase Plan, as amended and restated. |
| November 20, 2024 | 600 shares purchased on November 20, 2024, pursuant to the Issuer's 2014 Employee Stock Plan Purchase Plan, as amended and restated. |
| February 25, 2025 | Date of transaction: Acquisition of shares and stock options. |
| March 1, 2025 | Vesting Commencement Date for RSU grant and stock options. |
| February 24, 2035 | Expiration date for stock options. |
Keywords
Adverum Biotechnologies, Laurent Fischer, CEO, stock options, RSU, beneficial ownership, Form 4, stock split, ADVM
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.